Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL

Barclays PLC lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 15.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,359 shares of the medical research company’s stock after selling 28,519 shares during the period. Barclays PLC owned about 0.31% of Charles River Laboratories International worth $23,682,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its stake in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC acquired a new position in Charles River Laboratories International in the 1st quarter valued at $418,000. Fox Run Management L.L.C. purchased a new position in shares of Charles River Laboratories International during the 2nd quarter worth $400,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Charles River Laboratories International by 2.7% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,943 shares of the medical research company’s stock worth $8,488,000 after purchasing an additional 1,486 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter worth $803,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 0.9%

NYSE:CRL opened at $168.88 on Thursday. The company has a market cap of $8.31 billion, a PE ratio of -57.05, a P/E/G ratio of 2.86 and a beta of 1.64. The business’s 50 day moving average is $193.48 and its two-hundred day moving average is $181.14. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the prior year, the firm earned $2.66 EPS. The company’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Argus set a $200.00 price target on shares of Charles River Laboratories International in a report on Monday, November 17th. TD Cowen dropped their price objective on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a report on Friday, February 20th. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Finally, Citigroup lifted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $203.57.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.